Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,063.56 -21.63 (-1.99%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

3 Stocks to Buy and Hold Forever ↗

September 06, 2025

These stocks are built for the long run.

Via The Motley Fool

Topics Intellectual Property

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data ↗

September 05, 2025

Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.

Via Benzinga

Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day? ↗

September 05, 2025

The company's innovative engine continues to function well.

Via The Motley Fool

Topics World Trade

2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts ↗

September 05, 2025

Consensus price targets set by experts who follow these businesses are way above their recent prices.

Via The Motley Fool

Topics Stocks

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report ↗

September 03, 2025

Via Stocktwits

Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗

September 05, 2025

Viking aims to enter the billion-dollar weight loss drug market.

Via The Motley Fool

FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer ↗

September 04, 2025

Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results.

Via Benzinga

ETF Traders Are Quietly Positioning For Market Turbulence: Direxion ↗

September 04, 2025

Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves.

Via Benzinga

Topics ETFs

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗

September 04, 2025

Both companies have made significant progress in recent years.

Via The Motley Fool

The 6 Best Stocks to Buy Right Now in September (2025)! ↗

September 04, 2025

There is something for everyone in this list of excellent stocks to buy.

Via The Motley Fool

Where Will Eli Lilly Be in 3 Years? ↗

September 04, 2025

The weight-loss drug opportunity could approach $100 billion by the end of the decade.

Via The Motley Fool

Topics Intellectual Property

The Problem With Weight Loss Stocks ↗

September 03, 2025

There are new ways to tackle weight loss, but the stocks leading the way are lagging.

Via The Motley Fool

Topics Economy

After Copycat Boom, China's Drugmakers Target Global Generics ↗

September 03, 2025

Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.

Via Benzinga

Topics Supply Chain

This House of Representative Just Bought Up To $245K In Eli Lilly Stock ↗

September 03, 2025

Via Benzinga

Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly

September 03, 2025

From Defiance ETFs

Via GlobeNewswire

Is Novo Nordisk Stock a Buy Now? ↗

September 03, 2025

A 57% risk reduction for heart attacks and strokes sounds like an amazing result.

Via The Motley Fool

Inflation's Stubborn Grip: PCE Index and Fed's Dilemma

September 02, 2025

The specter of persistent inflation continues to loom large over the U.S. economy, keeping both consumers and policymakers on edge. Despite the Federal Reserve's aggressive campaign of interest rate...

Via MarketMinute

Topics Bonds Economy Supply Chain

EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank? ↗

September 02, 2025

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death ↗

September 02, 2025

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

Via Benzinga

Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks

September 01, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks ↗

August 30, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Topics Government

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment ↗

August 29, 2025

This could put pressure on Eli Lilly, which sells a competing drug called Kisunla.

Via Investor's Business Daily

The Great Rebalancing: Equity Markets Pivot from Tech Giants to Value and Cyclical Stocks

August 29, 2025

A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans ↗

August 29, 2025

Via Benzinga

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook ↗

August 29, 2025

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Via Benzinga

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗

August 29, 2025

The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.

Via Benzinga

Nvidia's $46.7 Billion Quarter Shows the AI Trade Is Alive and Well -- With Caveats ↗

August 29, 2025

Here's why investors aren't sure what to make of Nvidia earnings.

Via The Motley Fool

Topics Artificial Intelligence

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗

August 29, 2025

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

Via The Motley Fool

The Unsettling Dance: Robust Growth and Stubborn Inflation Challenge the Fed's Resolve

August 28, 2025

The U.S. economy currently navigates an intriguing, yet precarious, path as hypothetical Q2 2025 data suggests a robust rebound in Gross Domestic Product (GDP) growth. This economic buoyancy, however,...

Via MarketMinute

Topics Bonds Economy Energy

Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties

August 28, 2025

The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has...

Via MarketMinute

Topics Artificial Intelligence Economy Government

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.